MOVIPREP Drug Profile, 2023: MOVIPREP (ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate) drug patents, FDA exclusivity, litigation, sales revenuesDrugPatentWatch.com, 15 aug 2023 - 100 pagina's <h2>MOVIPREP Drug Profile, 2023</h2> <p>This report focuses on MOVIPREP and covers the following critical aspects of this drug:</p> <ul><li>United States patents</li> <li>FDA Paragraph IV patent challenges</li> <li>District Court patent litigation</li> <li>European supplementary protection certificates (SPCs)</li> <li>Clinical trials</li> <li>Drug prices</li> <li>Annual sales revenues</li> <li>Finished product suppliers</li> </ul> |
Veelvoorkomende woorden en zinsdelen
  &nearr &nearr acesulfame acesulfame K adenoma detection rate alkali metal alkaline earth metal aqueous solution ascorbic acid aspartame assess autism spectrum disorders bowel cleansing claim 31 claimed in claim cleansing agent cleansing compositions cleansing prior cleansing scales clinical trial colonic contraction Completed Norgine Phase components composition as claimed containers are sachets controlled trial drug dry composition comprises earth metal sulphate efficacy and safety fecal occult blood further comprising g/l sodium Gut Cleansing Solutions hyponatremia intake laxative liter low volume bowel metal or alkaline microbiome MOVIPREP patients undergoing colonoscopy patients with constipation pattern of contractions PEG-based PEG-ELS PEG-SD Pharmaceuticals Picoprep Plenvu polyethylene glycol polyethylene glycol PEG potassium chloride prior to colonoscopy randomised Safety and Tolerance salt of ascorbic salt thereof second containers second dry composition sodium ascorbate sodium chloride sodium sulfate solution of claim split dose split-dose treatment undergoing screening colonoscopy Unknown status versus Colopeg volume bowel preparation wherein